# A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

> **NCT06373146** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 392 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Mibavademab
- **DRUG:** Tirzepatide-Placebo
- **DRUG:** Mibavademab-Placebo

## Key facts

- **NCT ID:** NCT06373146
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-24
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-04-02
- **Target enrollment:** 392 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06373146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06373146, "A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06373146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*